sar439859
Small moleculeexperimental
Clinical trial activity
9 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Sep 8, 2017 (NCT03284957)
Timeline
Indications
Mechanism of action
- Estrogen receptor alphaDEGRADER
Estrogen receptor alpha degrader
Antagonises, leads to degradation
- Estrogen receptorINHIBITOR
Estrogen receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1ccc2c(c1)CCCC(c1ccc(Cl)cc1Cl)=C2c1ccc(O[C@H]2CCN(CCCF)C2)cc1- Mol. weight
- 554.49 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4475463 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05101564 | Phase 2 | Dec 31, 2021 | Department of Defense, Stanford University |
| NCT05126329 | Phase 1 | Dec 15, 2021 | Sanofi |
| NCT05128773 | Phase 3 | Nov 29, 2021 | European Organisation for Research and Treatment of Cancer, National Cancer Institute (NCI), Sanofi, University of Milan |
| NCT04940026 | Phase 1 | Jun 15, 2021 | Sanofi |
| NCT04478266 | Phase 3 | Oct 14, 2020 | Sanofi |
| NCT04191382 | Phase 2 | Nov 20, 2019 | Sanofi |
| NCT04059484 | Phase 2 | Sep 3, 2019 | Sanofi |
| NCT03816839 | Phase 1 | Mar 25, 2019 | Sanofi |
| NCT03284957 | Phase 1/Phase 2 (Phase 2) | Sep 8, 2017 | Sanofi |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 8 | 8 | 3 | 2017 |
| Department of Defense | Government | 1 | 0 | 1 | 2021 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2021 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Milan | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1